ACS nano · 2025
Self-Assembled Nanoparticle Vaccines Elicit Robust Protective Immune Responses against Type O Foot-and-Mouth Disease Virus Infection.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cao Nan, Li Yamei, Zhao Qiongqiong, Yao Manman, Ren Xujiao, Tian Linxing, Hu Zihui, Diao Feifei, Li Hehai, Lu Zengjun, Rao Guibo, Zhang Huawei, Li Kun, Cao Sheng, Li Xiangmin, Qian Ping
Аннотация
Foot-and-mouth disease virus (FMDV), a critical pathogen in the global livestock industry, has long been a focal point of international disease control strategies. This study developed a nanoparticle-based FMDV vaccine platform. We fused the FMDV immunodominant epitope (VP1-G-H-loop) and T-cell epitope (T3D) with the nanoparticle scaffold lumazine synthase (LS), efficiently producing the T3D-LS-LOOP nanoparticle vaccine using the prokaryotic expression system Escherichia coli (BL21). Mouse experiments showed that the T3D-LS-LOOP nanoparticle vaccine induced a more robust immune response than the LS-LOOP nanoparticle vaccine. To evaluate the role of different scaffolds in FMDV antigen presentation, we substituted the LS scaffold with Ferritin (Ft) and β-annulus peptide (β) nanoparticles, generating T3D-β-LOOP and T3D-Ft-LOOP nanoparticle proteins. The results demonstrated that the LS scaffold-mediated T3D-LS-LOOP nanoparticle vaccine induced the highest neutralizing antibody (NAb) titers (1:28.5) and an effective T-cell immune response, providing 100% protection in mice, outperforming T3D-Ft-LOOP (66.7%) and T3D-β-LOOP (83.3%) nanoparticle vaccines. Encouragingly, the T3D-LS-LOOP nanoparticle vaccine also induced high NAb titers against different lineages (Mya98/Cathay/PanAsia) of type O FMDV and a strong Th2-biased cellular immune response in swine, with no adverse reactions observed postvaccination, achieving complete protection against a type O FMDV challenge in swine.